Nimodipine information

Nimodipine
Clinical data
Trade names	Nimotop, Nymalize, others
AHFS/Drugs.com	Monograph
MedlinePlus	a689010
License data	US DailyMed: Nimodipine;
Pregnancy; category	AU: C; ;
Routes of; administration	Intravenous, by mouth
Drug class	Dihydropyridine calcium channel blocker
ATC code	C08CA06 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	13% (by mouth)
Protein binding	95%
Metabolism	Hepatic
Elimination half-life	8–9 hours
Excretion	Feces and Urine
Identifiers
	IUPAC name 3-(2-Methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	66085-59-4 ;
PubChem CID	4497;
IUPHAR/BPS	2523;
DrugBank	DB00393 ;
ChemSpider	4341 ;
UNII	57WA9QZ5WH;
KEGG	D00438 ;
ChEMBL	ChEMBL1428 ;
CompTox Dashboard (EPA)	DTXSID5023370 ;
ECHA InfoCard	100.060.096
Chemical and physical data
Formula	C21H26N2O7
Molar mass	418.446 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	125 °C (257 °F)
	SMILES O=C(OC(C)C)\C1=C(\N/C(=C(/C(=O)OCCOC)C1c2cccc([N+]([O-])=O)c2)C)C;
	InChI InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 ; Key:UIAGMCDKSXEBJQ-UHFFFAOYSA-N ;
	(verify)

Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.

It was patented in 1971^[3] and approved for medical use in the US in 1988.^[4] It was approved for medical use in Germany in 1985.^[5]

^ "Nimodipine Use During Pregnancy". Drugs.com. March 15, 2019. Retrieved April 11, 2020.
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.
^ GB 1358951, Meyer H, Bossert F, Vater W, Stoepel KN, "New esters, their production, and their medicinal use", published 1974-07-03, assigned to Bayer AG
^ "US FDA NDA 018869" (New drug approval from the US FDA). Drugs@FDA.gov Approved Drugs. Food and Drug Administration of the United States (FDA). December 28, 1988. Retrieved April 11, 2019. Nimodipine (...) approved for the treatment of high blood pressure (...)
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495.

[Drugs.com_pregnancy-1] "Nimodipine Use During Pregnancy". Drugs.com. March 15, 2019. Retrieved April 11, 2020.

[FDA-AllBoxedWarnings-2] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.

[3] GB 1358951, Meyer H, Bossert F, Vater W, Stoepel KN, "New esters, their production, and their medicinal use", published 1974-07-03, assigned to Bayer AG

[original-US-marketing-approval-4] "US FDA NDA 018869" (New drug approval from the US FDA). Drugs@FDA.gov Approved Drugs. Food and Drug Administration of the United States (FDA). December 28, 1988. Retrieved April 11, 2019. Nimodipine (...) approved for the treatment of high blood pressure (...)

[5] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495.

Nimodipine information

and 29 Related for: Nimodipine information

Nimodipine

Subarachnoid hemorrhage

Ketamine

Calcium channel blocker toxicity

Cocaine

Diltiazem

Pharmacodynamics

Hantzsch pyridine synthesis

Calcium channel blocker

ATC code C08

List of cardiac pharmaceutical agents

Vasospasm

Gabapentin

Lorazepam

Topiramate

Cholesterol

Benzocaine

Benzonatate

Phenibut

Corticosteroid

Pregabalin

Hydrocortisone

Cortisol

Kava

Propranolol

Spironolactone

Steroid

Baclofen

Amlodipine